Schlienger R - Search Results

1

Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia.

Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, Gomes M, Ribeiro I, Walter V, Virtanen M, Schlienger R, Cousin M, Chipimo M, Sullivan FM. Manyando C, et al. Among authors: schlienger r. Malar J. 2010 Sep 1;9:249. doi: 10.1186/1475-2875-9-249. Malar J. 2010. PMID: 20809964 Free PMC article.

2

Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting.

Kabanywanyi AM, Mulure N, Migoha C, Malila A, Lengeler C, Schlienger R, Genton B. Kabanywanyi AM, et al. Among authors: schlienger r. Malar J. 2010 Jul 14;9:205. doi: 10.1186/1475-2875-9-205. Malar J. 2010. PMID: 20630066 Free PMC article.

3

Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.

Kabanywanyi AM, Lengeler C, Kasim P, King'eng'ena S, Schlienger R, Mulure N, Genton B. Kabanywanyi AM, et al. Among authors: schlienger r. Malar J. 2010 Feb 11;9:48. doi: 10.1186/1475-2875-9-48. Malar J. 2010. PMID: 20149235 Free PMC article. Clinical Trial.

4

Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K.

Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Arana A, et al. Among authors: schlienger rg. Br J Dermatol. 2010 Nov;163(5):1036-43. doi: 10.1111/j.1365-2133.2010.09887.x. Br J Dermatol. 2010. PMID: 20545690

5

Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.

Arellano FM, Arana A, Wentworth CE, Fernández-Vidaurre C, Schlienger RG, Conde E. Arellano FM, et al. J Allergy Clin Immunol. 2009 May;123(5):1111-6, 116.e1-13. doi: 10.1016/j.jaci.2009.02.028. Epub 2009 Apr 10. J Allergy Clin Immunol. 2009. PMID: 19361841

6

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.

Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD. Schneeweiss S, et al. Dermatology. 2009;219(1):7-21. doi: 10.1159/000209289. Epub 2009 Mar 17. Dermatology. 2009. PMID: 19293564

7

Academic detailing improves identification and reporting of adverse drug events.

Schlienger RG, Lüscher TF, Schoenenberger RA, Haefeli WE. Schlienger RG, et al. Pharm World Sci. 1999 Jun;21(3):110-5. doi: 10.1023/a:1008631926100. Pharm World Sci. 1999. PMID: 10427579 Clinical Trial.

8

[Anticonvulsant hypersensitivity syndrome. 2 case reports and an overview].

Ronsdorf A, Schlienger RG, Haefeli WE, Martin-Facklam M, Schoenenberger RA. Ronsdorf A, et al. Among authors: schlienger rg. Praxis (Bern 1994). 1999 Oct 7;88(41):1660-6. Praxis (Bern 1994). 1999. PMID: 10546511 Review. German.

9

Risk of cataract in patients treated with statins.

Schlienger RG, Haefeli WE, Jick H, Meier CR. Schlienger RG, et al. Arch Intern Med. 2001 Sep 10;161(16):2021-6. doi: 10.1001/archinte.161.16.2021. Arch Intern Med. 2001. PMID: 11525705

10

Rhabdomyolysis in association with simvastatin and amiodarone.

Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Roten L, et al. Ann Pharmacother. 2004 Jun;38(6):978-81. doi: 10.1345/aph.1D498. Epub 2004 Apr 6. Ann Pharmacother. 2004. PMID: 15069169

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters